Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Aaron P MitchellAkriti Mishra MezaKatherine S PanageasAllison Lipitz-SnydermanAzeez FarookiMichael J MorrisPublished in: Prostate cancer and prostatic diseases (2022)
Two-thirds of patients with mCRPC and bone metastases received BMAs within 180 days after initiating CDT. A greater proportion of patients without bone metastasis may warrant BMA therapy for osteoporotic fracture prevention. Some patients with bone metastasis may be able to delay BMA initiation until CRPC.